natgillin/translations-raw huggingface dataset:
Melosus is available as an oral (taken by mouth) suspension as 0.5 mg/ml for use in cats and guinea pigs and 1.5 mg/ml for use in dogs.
Zdravilo Melosus je na voljo v obliki peroralne suspenzije (ki se vzame skozi usta) v odmerku 0,5 mg/ml za uporabo pri mačkah in morskih prašičkih ter v odmerku 1,5 mg/ml za uporabo pri psih.
Because Melosus is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Melosus generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
This means that Melosus contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
To pomeni, da vsebuje enako učinkovino in ima enak način delovanja kot referenčno zdravilo Metacam, ki je že odobreno v Evropski uniji (EU).
What is Melosus and what is it used for?
Kaj je zdravilo Melosus in za kaj se uporablja?
Melosus contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Melosus vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
Melosus is an anti-inflammatory medicine used in dogs, cats and guinea pigs.
Melosus je protivnetno zdravilo, ki se uporablja za zdravljenje psov, mačk in morskih prašičkov.
As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of inflammation.
Prostaglandini sprožajo vnetje, bolečino in izcejanje tekočine (izcejanje tekočine iz krvnih žil med vnetnim procesom) ter povišano telesno temperaturo, meloksikam pa te bolezenske znake zmanjšuje.
For further information about using Melosus, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila Melosus glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Previously known as Melocam.
Predhodno znano kot zdravilo Melocam.
Safety information has been included in the summary of product characteristics and the package leaflet for Melosus, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila Melosus in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
The dose depends on the animal, the bodyweight and condition and is given mixed with food or directly into the mouth for dogs and cats and directly into the mouth for guinea pigs.
Zdravilo se daje pomešano s hrano ali neposredno v gobec pri psih in mačkah ter neposredno v gobec pri morskih prašičkih.
Moreover, it is used to lessen pain and inflammation in chronic musculo-skeletal disorders.
Poleg tega se uporablja tudi za lajšanje bolečin in umirjanju vnetja pri kostno-mišičnih obolenjih.
In guinea pigs Melosus is used to reduce pain after soft tissue surgery such as castration.
Pri morskih prašičkih se zdravilo Melosus uporablja za lajšanje bolečin po kirurških posegih na mehkih tkivih, kot je na primer kastracija.
Melosus contains the active substance meloxicam and is a ‘generic medicine'.
Zdravilo Melosus vsebuje učinkovino meloksikam in je generično zdravilo.
How does Melosus work?
Kako zdravilo Melosus deluje?
In cats, Melosus is used to reduce pain and inflammation after orthopaedic and minor soft tissue surgery.
Pri mačkah se zdravilo Melosus uporablja za lajšanje bolečin in umirjanje vnetja po ortopedskih kirurških posegih in manjših kirurških posegih na mehkih tkivih.
How has Melosus been studied?
Kako je bilo zdravilo Melosus raziskano?
Therefore, the Agency's view was that, as for Metacam, the benefit of Melosus outweighs the identified risk and it can be authorised for use in the EU.
Zato je menila, da koristi zdravila Melosus enako kot pri zdravilu Metacam odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
Melosus can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Melosus je le na recept.
How is Melosus used?
Kako se zdravilo Melosus uporablja?
In dogs, Melosus is used to lessen inflammation and pain in musculo-skeletal disorders.
Zdravilo Melosus se pri psih uporablja za umirjanje vnetja in lajšanje bolečin pri kostno-mišičnih obolenjih.
The precautions are the same as for the reference medicine since Melosus is a generic medicine.
Ker je zdravilo Melosus generično zdravilo, so previdnostni ukrepi enaki kot pri referenčnem zdravilu.
• hypertension;
• hipertenzije,
The areas harmonised include:
Poglavja, ki jih je treba uskladiti, so:
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom, as well as in Iceland and Norway.
Zdravilo Plendil in povezana imena se trenutno tržijo v naslednjih državah članicah EU: v Avstriji, Belgiji, Bolgariji, na Hrvaškem, Cipru, v Češki republiki, na Danskem, v Estoniji, na Finskem, v Franciji, Nemčiji, Grčiji, na Madžarskem, Irskem, v Italiji, Latviji, Litvi, Luksemburgu, na Malti, Nizozemskem, Poljskem, Portugalskem, v Romuniji, na Slovaškem, v Španiji, na Švedskem in v Združenem kraljestvu ter na Islandiji in Norveškem.
Why was Plendil reviewed?
Zakaj je bilo zdravilo Plendil pregledano?
Plendil and associated names have been authorised in EU Member States through national procedures since 1987.
Zdravilo Plendil in povezana imena so bila v državah članicah EU odobrena po nacionalnih postopkih in so na voljo od leta 1987.
Plendil is a medicine used to treat hypertension (high blood pressure).
Plendil je zdravilo, ki se uporablja za zdravljenje hipertenzije (visokega krvnega tlaka).
• stable angina pectoris (a type of angina pectoris that occurs with activity or stress).
• stabilne angine pektoris (vrste angine pektoris, ki se pojavi ob telesni dejavnosti ali stresu).
After reviewing the available data supporting the medicine's use, the CHMP agreed that Plendil can be used to treat the following:
Po pregledu razpoložljivih podatkov, ki podpirajo uporabo zdravila, se je odbor CHMP strinjal, da se lahko zdravilo Plendil uporablja za zdravljenje:
The European Commission issued an EU-wide legally binding decision to implement these changes on 16 December 2014.
Evropska komisija je 16. decembra 2014 izdala pravno zavezujoči sklep o izvajanju navedenih sprememb, ki velja za celotno EU.
In view of this, on 12 November 2013 the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Plendil in the EU.
Zaradi tega je Evropska komisija 12. novembra 2013 zadevo napotila na odbor CHMP, da bi uskladili dovoljenja za promet z zdravilom Plendil v EU.
The CHMP also harmonised other sections of the SmPC, including sections 4.4 (special warnings and precautions for use), 4.6 (fertility, pregnancy and lactation) and 4.8 (side effects).
Odbor CHMP je uskladil tudi druga poglavja povzetka glavnih značilnosti zdravila, vključno s poglavji 4.4 (Posebna opozorila in previdnostni ukrepi), 4.6 (Plodnost, nosečnost in dojenje) ter 4.8 (Neželeni učinki).
The medicine is available as prolonged release tablets (2.5, 5 and 10 mg) which release the active substance over an extended period of time.
Na voljo je v obliki tablet s podaljšanim sproščanjem (2,5, 5 in 10 mg), iz katerih se zdravilna učinkovina sprošča dlje časa.
On 23 October 2014, the European Medicines Agency completed a review of Plendil and associated names.
Evropska agencija za zdravila je 23. oktobra 2014 zaključila pregled zdravila Plendil in povezanih imen.
The CHMP agreed to include the following contraindications in the product information: hypersensitivity (allergy) to felodipine or to any other ingredients; pregnancy; decompensated heart failure (worsening of symptoms in patients with heart problems); acute myocardial infarction (heart attack); unstable angina pectoris (a type of chest pain that happens suddenly, even at rest or asleep, and which may lead to a heart attack), and certain types of heart valve and bloodflow obstructions.
Odbor CHMP se je strinjal, da se v informacije o zdravilu vključijo naslednje kontraindikacije: preobčutljivost za (alergija na) felodipin ali katero koli drugo sestavino; nosečnost; dekompenzirano srčno popuščanje (poslabšanje simptomov pri bolnikih, ki imajo težave s srcem); akutni miokardni infarkt (srčna kap); nestabilna angina pektoris (vrsta bolečine v prsnem košu, ki se pojavi nenadoma, tudi med mirovanjem ali spanjem, in lahko povzroči srčno kap) ter določene vrste obstrukcije srčne zaklopke in krvnega pretoka.
What is Plendil?
Kaj je zdravilo Plendil?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Plendil and associated names in the European Union (EU).
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je potrebna uskladitev informacij o predpisovanju zdravila Plendil in povezanih imen v Evropski uniji (EU).
Having harmonised the indications, the CHMP also harmonised recommendations on the doses and recommendations for special populations.
Po uskladitvi indikacij je odbor CHMP uskladil tudi priporočila za odmerjanje in priporočila za posebne populacije bolnikov.
The Committee also agreed that Plendil should no longer be recommended to treat ‘vasospastic angina pectoris' (another type of angina pectoris caused by spasms in the vessels supplying blood to the heart), because the available data to support this use were considered too limited.
Odbor se je prav tako strinjal, da se zdravilo Plendil ne sme več priporočati za zdravljenje „vazospastične angine pektoris“ (še ene vrste angine pektoris, ki jo povzročajo krči v žilah, ki dovajajo kri v srce), saj je ocenil, da so razpoložljivi podatki, s katerimi bi lahko podprli tovrstno uporabo, preveč omejeni.
As Plendil has been authorised in the EU via national procedures, this has led to divergences across Member States in the way the medicine can be used, as seen in differences in the SmPCs (summary of product characteristics), labelling and package leaflets in the countries where the medicine is marketed.
Ker je bilo zdravilo Plendil v EU odobreno po nacionalnih postopkih, so se pojavile razlike med državami članicami glede tega, kako se zdravilo lahko uporablja, kar se odraža v razlikah med povzetki glavnih značilnosti zdravila, označevanji in navodili za uporabo v državah, v katerih se zdravilo trži.
It is also used to treat angina pectoris (chest pain that occurs due to problems with the blood flow to the heart).
Prav tako se uporablja za zdravljenje angine pektoris (bolečine v prsnem košu, ki je posledica težav z dotokom krvi v srce).
The company that markets these medicines is AstraZeneca.
Zdravila trži farmacevtska družba AstraZeneca.
The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets for Plendil should be harmonised across the EU.
Odbor CHMP je na podlagi predloženih podatkov in notranje znanstvene razprave menil, da je treba uskladiti povzetke glavnih značilnosti zdravila, označevanje in navodilo za uporabo za zdravilo Plendil po vsej EU.
16 December 2014
16. december 2014 EMA/790566/2014
The labelling and package leaflet were also revised in line with the changes to the SmPC.
Prav tako je v skladu s spremembami povzetka glavnih značilnosti zdravila popravil in dopolnil označevanje in navodilo za uporabo.
Oral use blister (PVC/PVDCalu/PET/paper)
Al/PET/papir)
200 mg Film-coated tablet
200mg filmsko obložena tableta peroralna uporaba pretisni omot (PVC/PVDC
Ref. EMEA/CHMP/494721/2008
EMEA/CHMP/494741/2008
Losartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).
Losartan lahko tudi upočasni napredovanje diabetične nefropatije ter je namenjen tudi za upočasnitev napredovanja ledvične bolezni pri bolniki s sladkorno boleznijo tipa 2 in mikroalbuminurijo (>30 mg/24 ur) ali proteinurijo (>900 mg/24 ur).
Cozaar and associated names, 12,5 mg, 25mg, 50 mg, 100 mg, film-coated tablets is an orally active angiotensin II (Ang- II) receptor antagonist, losartan, acting on the AT1 receptor subtype, thus blocking the effect of Ang-II in the renin angiotensin system (RAS) cascade.
Zdravilo Cozaar in povezana imena, 12,5 mg, 25 mg, 50 mg, 100 mg, filmsko obložene tablete, vsebuje losartan, peroralno aktivni antagonist receptorjev angiotenzina II (Ang- II), delujoč na receptorje podtipa AT1, ki na ta način blokira učinek Ang-II v kaskadi renin-angiotenzinskega sistema (RAS).
On 23 February 2007, Denmark presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised summaries of product characteristics, package leaflet and labelling of the medicinal product Cozaar and associated names for the following indications: Treatment of essential hypertension; Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus with proteinuria > 0.5 g/day as part of an antihypertensive treatment; Reduction of risk of stroke in hypertensive patients with left ventricular hypertrophy documented by ECG; Treatment of chronic heart failure (in patients ≥ 60 years), when treatment with ACE inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication.
Dne 23. februarja 2007 je Danska agenciji EMEA predložila napotitev v skladu s členom 30 Direktive 2001/83/ES, kakor je bila spremenjena, da bi tako uskladili nacionalno odobrene povzetke glavnih značilnosti zdravila, navodila za uporabo in označevanje za zdravilo Cozaar in povezana imena za naslednje indikacije: zdravljenje esencialne hipertenzije; zdravljenje ledvične bolezni pri bolnikih s hipertenzijo in sladkorno boleznijo tipa 2 s proteinurijo > 0,5 g/dan kot del antihipertenzivnega zdravljenja; zmanjšanje tveganja kapi pri hipertenzivnih bolnikih s hipertrofijo levega prekata, dokazano z EKG-jem; zdravljenje kroničnega srčnega popuščanja (pri bolnikih, starih 60 let ali več), če je zdravljenje z zaviralci ACE ocenjeno kot neprimerno zaradi nezdružljivosti, zlasti kašlja, ali kontraindikacij.
The CHMP gave a positive opinion on 24 April 2008 recommending the harmonisation of the SPC, labelling and package leaflet for Cozaar and associated names.
CHMP je 24. aprila 2008 izdal pozitivno mnenje, s katerim priporoča uskladitev povzetkov glavnih značilnosti zdravila, označevanja in navodila za uporabo za zdravilo Cozaar in povezana imena.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Cozaar and associated names International Non-Proprietary Name (INN): losartan
Mednarodno nelastniško ime (INN): losartan
Incresync alogliptin / pioglitazone
Incresync alogliptin/pioglitazon
The European Commission granted a marketing authorisation valid throughout the European Union for Incresync on 19 September 2013.
Evropska komisija je dovoljenje za promet z zdravilom Incresync, veljavno po vsej Evropski uniji, odobrila 19. septembra 2013.
It is taken by mouth once daily.
Zdravilo se jemlje peroralno enkrat na dan.
Other information about Incresync
Druge informacije o zdravilu Incresync
HbA1c levels were measured after 26 weeks in the first study and 52 weeks in the second study.
Vrednosti HbA1c so v prvi študiji izmerili po 26 tednih, v drugi študiji pa po 52 tednih.
Incresync has been studied in two main studies involving 1,296 patients with type-2 diabetes that was not well controlled by previous treatment.
Zdravilo Incresync so proučevali v dveh glavnih študijah, v kateri je bilo vključenih 1 296 bolnikov s sladkorno boleznijo tipa 2, ki ni bila dobro urejena s prejšnjim zdravljenjem.
The full EPAR for Incresync can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Incresync je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Incresync?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Incresync?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Incresync's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Incresync večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
This is a summary of the European public assessment report (EPAR) for Incresync.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Incresync.
What is Incresync and what is it used for?
Kaj je zdravilo Incresync in za kaj se uporablja?
Alogliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Alogliptin je zaviralec dipeptidil-peptidaze-4 (DPP 4).
It is not intended to provide practical advice on how to use Incresync.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
A risk management plan has been developed to ensure that Incresync is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Incresync je bil pripravljen načrt obvladovanja tveganj.
Pioglitazone is authorised in the EU as Actos and associated names.
Pioglitazon je v EU odobren kot zdravilo Actos in povezana imena.
What benefits of Incresync have been shown in studies?
Kakšne koristi je zdravilo Incresync izkazalo v študijah?
Incresync is available as tablets (12.5 or 25 mg alogliptin and 30 mg pioglitazone; 12.5 or 25 mg alogliptin and 45 mg pioglitazone) and can only be obtained with a prescription.
Zdravilo Incresync je na voljo v obliki tablet (12,5 ali 25 mg alogliptina in 30 mg pioglitazona; 12,5 ali 25 mg alogliptina in 45 mg pioglitazona) in se izdaja le na recept.
In addition, the company that markets Incresync will produce educational materials for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Poleg tega bo družba, ki trži zdravilo Incresync, zagotovila izobraževalno gradivo za zdravnike, ki bodo predpisovali zdravilo, v katerem bodo obravnavana možna tveganja za srčno popuščanje in raka sečnega mehurja, povezana z zdravili, ki vsebujejo pioglitazon, merila za izbiro bolnikov in potreba po rednem spremljanju zdravljenja, ki ga je treba prekiniti, če bolnikom ne koristi več.
Why is Incresync approved?
Zakaj je bilo zdravilo Incresync odobreno?
If patients are also taking metformin, lower doses of metformin or pioglitazone may need to be given to reduce the risk of hypoglycaemia (low blood sugar levels).
Če bolniki jemljejo tudi metformin, bo morda treba dajati manjše odmerke metformina ali pioglitazona za zmanjšanje tveganja za hipoglikemijo (nizke ravni sladkorja v krvi).
The dose should be lowered in patients with moderately reduced kidney function.
Odmerek je treba zmanjšati pri bolnikih z zmerno okvaro delovanja ledvic.
Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Pioglitazon poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da lahko telo bolje izrablja insulin, ki ga proizvaja.
The most common side effects with Incresync (which may affect up to 1 in 10 people) are upper respiratory tract infections (colds), sinusitis, headache, nausea (feeling sick), dyspepsia (heartburn), abdominal pain (tummy ache), pruritus (itching), myalgia (muscle pain), peripheral oedema (swelling in arms and legs) and weight gain.
Najpogostejši neželeni učinki zdravila Incresync (ki lahko prizadenejo največ 1 osebo od 10) so okužbe zgornjih dihal (prehladi), sinusitis, glavobol, navzea (slabost), dispepsija (zgaga), bolečine v trebuhu, pruritus (srbenje), mialgija (bolečine v mišicah), periferni edem (otekanje rok in nog) in povečanje telesne mase.
The choice of tablet strength to start with depends on the patient's current treatment.
Jakost tablete na začetku zdravljenja se izbere glede na zdravljenje, ki ga bolnik trenutno prejema.
What are the risks associated with Incresync?
Kakšna tveganja so povezana z zdravilom Incresync?
It must also not be used in patients who have or have ever had heart failure or bladder cancer, those with reduced liver function, diabetic ketoacidosis (a serious condition that can occur in diabetes), or blood in the urine that has not been properly investigated.
Prav tako ga ne smejo uporabljati bolniki, ki imajo ali so kdaj imeli srčno popuščanje ali raka sečnega mehurja, bolniki z okvarjenim delovanjem jeter, diabetično ketoacidozo (resen zaplet, ki se lahko pojavi pri sladkorni bolezni) ali s krvjo v urinu, ki še ni bila ustrezno preiskana.
Incresync must not be used in patients who are hypersensitive (allergic) to the active substances or any of the ingredients or who have had serious allergic reactions to any dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Zdravila Incresync ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) zdravilni učinkovini ali katero koli sestavino zdravila, in bolniki, ki so imeli hude alergijske reakcije na kateri koli zaviralec dipeptidil-peptidaze-4 (DPP 4).
Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina za uravnavanje ravni glukoze v krvi ali pri kateri telo ne more učinkovito izrabljati insulina.
Regarding safety, Incresync's safety profile was consistent with that seen with the individual components.
V zvezi z varnostjo zdravila Incresync je njegov varnostni profil skladen s profilom posameznih učinkovin.
Alogliptin does not work when the blood glucose is low.
Alogliptin ne deluje, če je raven glukoze v krvi nizka.
HbA1c levels give an indication of how well the blood glucose is controlled.
Vrednosti HbA1c kažejo, kako dobro je uravnavana glukoza v krvi.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Incresync, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Incresync vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In both studies, the main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
V obeh študijah je bilo glavno merilo učinkovitosti sprememba vrednosti glikoziliranega hemoglobina (HbA1c), tj. deleža hemoglobina v krvi, vezanega na glukozo.
• together with metformin, in patients who are not satisfactorily controlled with a combination of pioglitazone and metformin.
• skupaj z metforminom pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo urejena s kombinacijo pioglitazona in metformina.
The CHMP therefore considered that the combination of alogliptin and pioglitazone in Incresync is of benefit to patients.
Zato je CHMP menil, da je kombinacija alogliptina in pioglitazona v zdravilu Incresync koristna za bolnike.